[go: up one dir, main page]

WO2010150144A3 - Low dose pharmaceutical compositions of celecoxib - Google Patents

Low dose pharmaceutical compositions of celecoxib Download PDF

Info

Publication number
WO2010150144A3
WO2010150144A3 PCT/IB2010/052722 IB2010052722W WO2010150144A3 WO 2010150144 A3 WO2010150144 A3 WO 2010150144A3 IB 2010052722 W IB2010052722 W IB 2010052722W WO 2010150144 A3 WO2010150144 A3 WO 2010150144A3
Authority
WO
WIPO (PCT)
Prior art keywords
celecoxib
pharmaceutical compositions
low dose
dose pharmaceutical
reduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2010/052722
Other languages
French (fr)
Other versions
WO2010150144A2 (en
Inventor
Sanjay Mate
Ritesh Kapoor
Munish Talwar
Girish Kumar Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wockhardt Research Centre
Original Assignee
Wockhardt Research Centre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Research Centre filed Critical Wockhardt Research Centre
Publication of WO2010150144A2 publication Critical patent/WO2010150144A2/en
Anticipated expiration legal-status Critical
Publication of WO2010150144A3 publication Critical patent/WO2010150144A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

There is provided a reduced dose pharmaceutical composition comprising celecoxib or salts thereof wherein the dose of the celecoxib is 120-185mg. The composition of the present invention may exhibit improved bioavailability along with reduced undesirable side effects. The invention also relates to processes for the preparation of such compositions.
PCT/IB2010/052722 2009-06-25 2010-06-17 Low dose pharmaceutical compositions of celecoxib Ceased WO2010150144A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN1509/MUM/2009 2009-06-25
IN1505MU2009 2009-06-25
IN1510/MUM/2009 2009-06-25
IN1509MU2009 2009-06-25
IN1510MU2009 2009-06-25
IN1505/MUM/2009 2009-06-25

Publications (2)

Publication Number Publication Date
WO2010150144A2 WO2010150144A2 (en) 2010-12-29
WO2010150144A3 true WO2010150144A3 (en) 2012-06-14

Family

ID=43216427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/052722 Ceased WO2010150144A2 (en) 2009-06-25 2010-06-17 Low dose pharmaceutical compositions of celecoxib

Country Status (1)

Country Link
WO (1) WO2010150144A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140100170A (en) * 2013-02-05 2014-08-14 에스케이케미칼주식회사 oral administrable celecoxib composition
WO2014205226A1 (en) * 2013-06-19 2014-12-24 Kashiv Pharma, Llc Self-nanoemulsion of poorly soluble drugs
WO2016191744A1 (en) * 2015-05-28 2016-12-01 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
US10722456B2 (en) * 2016-05-27 2020-07-28 Dr. Reddy's Laboratories Ltd Oral composition of celecoxib for treatment of pain
EP4267132A1 (en) 2020-12-28 2023-11-01 Dr. Reddy's Laboratories Ltd. Celecoxib for treating pain
CN113750043A (en) * 2021-09-18 2021-12-07 山东省药学科学院 Celecoxib self-emulsifying oral liquid and preparation method thereof
KR102641708B1 (en) * 2021-10-29 2024-02-29 단국대학교 천안캠퍼스 산학협력단 Celecoxib-loaded solid dispersion with alkalizing agent and methods for preparing the same
CN115998689B (en) * 2023-01-16 2025-03-18 五邑大学 A kind of celecoxib solid self-microemulsification nanoparticles and its preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050267190A1 (en) * 1999-12-08 2005-12-01 Hageman Michael J Solid-state form of celecoxib having enhanced bioavailability
WO2006079923A2 (en) * 2005-01-31 2006-08-03 Pharmacia & Upjohn Company Llc Form iv crystalline celecoxib
WO2009063367A1 (en) * 2007-11-15 2009-05-22 Pfizer Products Inc. Dosage forms comprising celecoxib providing both rapid and sustained pain relief

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE233245T1 (en) 1993-11-30 2003-03-15 Searle & Co SUBSTITUTED PYRAZOLYL-BENZENESULFONAMIDES AND THEIR USE AS CYCLOOXYGENASEII INHIBITORS
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5972986A (en) 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
IL144760A0 (en) 1999-12-08 2002-06-30 Pharmacia Corp Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
US6589557B2 (en) 2000-06-15 2003-07-08 Acusphere, Inc. Porous celecoxib matrices and methods of manufacture thereof
CA2436570A1 (en) 2000-12-06 2002-06-13 Pharmacia Corporation Rapidly dispersing pharmaceutical composition comprising effervescent agents
KR20030041577A (en) 2001-11-20 2003-05-27 디디에스텍주식회사 Solid dispersions containing substituted cyclodextrin and insoluble drug and their preparations
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
CA2537029C (en) 2003-11-26 2013-03-12 Likan Liang Micellar systems useful for delivery of lipophilic or hydrophobic compounds
US20060068007A1 (en) 2004-09-24 2006-03-30 Boehringer Ingelheim Pharmaceuticals, Inc. Class of surfactant-like materials
EP2091519B1 (en) 2006-11-30 2015-06-24 Bend Research, Inc Multiparticulates of spray-coated drug and polymer on a meltable core
EP1961412A1 (en) 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Self-microemulsifying drug delivery systems
EP2134327A1 (en) 2007-03-13 2009-12-23 Sandoz AG Pharmaceutical compositions of poorly soluble drugs
CA2677670C (en) 2007-03-20 2010-08-03 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050267190A1 (en) * 1999-12-08 2005-12-01 Hageman Michael J Solid-state form of celecoxib having enhanced bioavailability
WO2006079923A2 (en) * 2005-01-31 2006-08-03 Pharmacia & Upjohn Company Llc Form iv crystalline celecoxib
WO2009063367A1 (en) * 2007-11-15 2009-05-22 Pfizer Products Inc. Dosage forms comprising celecoxib providing both rapid and sustained pain relief

Also Published As

Publication number Publication date
WO2010150144A2 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
WO2010150144A3 (en) Low dose pharmaceutical compositions of celecoxib
WO2011012816A3 (en) Pharmaceutical formulation
WO2010134047A3 (en) Liquid dosage forms of isotretinoin
WO2012042371A3 (en) Pharmaceutical composition
WO2010092090A3 (en) Novel salts of sitagliptin
WO2010108074A3 (en) Inhibitors of pi3 kinase
EP3699176A3 (en) Antiviral compounds
ZA201206254B (en) Novel salts for the manufacture of pharmaceutical compositions
MY187718A (en) Pharmaceutical formulations
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
MX348654B (en) Pharmaceutical composition with improved bioavailability for high melting hydrophobic compound.
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
WO2010129918A8 (en) Triptolide prodrugs
WO2010129057A8 (en) Tetracycline compounds
WO2011123536A8 (en) Polycyclic tetracycline compounds
HK1209741A1 (en) Tricyclic compounds for inhibiting the cftr channel
WO2008001201A3 (en) Pharmaceutical compositions of clopidogrel
WO2010049449A3 (en) Novel salts of sunitinib
WO2009118589A3 (en) Orally disintegrating compositions of rhein or diacerein
WO2011015287A3 (en) Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
WO2010132670A3 (en) Pentacycline compounds
TN2012000105A1 (en) Spirolactam derivatives and uses of same
IN2012DN04868A (en)
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2012014052A3 (en) Novel coated extended release pharmaceutical compositions containing paliperidone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10742881

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10742881

Country of ref document: EP

Kind code of ref document: A2